Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-08
DOI
10.1038/s41416-020-0980-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta‐analysis
- (2020) Leila T. Tchelebi et al. CANCER
- Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
- (2020) Eva Versteijne et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of COVID-19 for cancer patients
- (2020) Yang Xia et al. LANCET ONCOLOGY
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
- (2020) Wenhua Liang et al. LANCET ONCOLOGY
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
- (2020) Qun Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database
- (2020) Michael Xiang et al. RADIOTHERAPY AND ONCOLOGY
- Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
- (2020) Wei-jie Guan et al. EUROPEAN RESPIRATORY JOURNAL
- Clinical course and mortality risk of severe COVID-19
- (2020) Paul Weiss et al. LANCET
- SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
- (2020) Jing Yu et al. JAMA Oncology
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials
- (2017) Fausto Petrelli et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies
- (2017) Han-Xiang Zhan et al. Cancer Medicine
- A phase-I trial of pre‐operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the ‘SPARC’ trial protocol
- (2016) Daniel L. P. Holyoake et al. BMC CANCER
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages
- (2015) Jun Yu et al. GUT
- Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study
- (2014) Juan W. Valle et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started